Zentalis appoints Cam Gallagher as President, effective May 30, 2022

Zentalis Pharmaceuticals, Inc.

Cam Gallagher, formerly Executive Director and Board member, appointed President, replacing Kimberly Blackwell.
Initial annual base salary: $560,000; eligible for 50% target bonus.
Received stock options for 333,218 shares and RSUs for 111,072 shares, vesting over 4 years.
Gallagher has ties to Recurium IP, which received $10M milestone fees from Zentalis in 2021.
Employment is at-will; severance includes 12 months salary plus prorated bonus on qualifying termination.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Cam S. Gallagher

President

ZNTL · Zentalis Pharmaceuticals, Inc.

Effective: 2022-05-30
Filed: May 31, 2022, 7:59 PM ET

On May 25, 2022, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) appointed Cam S. Gallagher, a current Executive Director of the Company and a current member of the Board, as President of the Company, succeeding Kimberly Blackwell in such role, effective as of May 30, 2022 (the “Commencement Date”).

Departed

Kimberly Blackwell

President

ZNTL · Zentalis Pharmaceuticals, Inc.

Effective: 2022-05-30
Successor: Cam S. Gallagher
Filed: May 31, 2022, 7:59 PM ET

succeeding Kimberly Blackwell in such role

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Cam S. Gallagher was appointed as President at Zentalis Pharmaceuticals, Inc..

Action: appointed
Role: President

Exact text from the filing

On May 25, 2022, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) appointed Cam S. Gallagher, a current Executive Director of the Company and a current member of the Board, as President of the Company, succeeding Kimberly Blackwell in such role, effective as of May 30, 2022 (the “Commencement Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Kimberly Blackwell departed as President at Zentalis Pharmaceuticals, Inc..

Action: departed
Role: President

Exact text from the filing

succeeding Kimberly Blackwell in such role

View on SEC.gov

Zentalis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001725160-22-000114

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.